NCT03519243已完成2 期
Randomized Open-Label Comparative Study of the Efficacy and Safety of BCD-131 (JSC BIOCAD, Russia) and Mircera (F. Hoffmann-La Roche Ltd, Switzerland) in Treatment of Anemia in Chronic Kidney Disease Patients on Dialysis
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- Biocad
- 入组人数
- 75
- 试验地点
- 4
- 主要终点
- Change in Hemoglobin (Hb) Concentration From Baseline to the Evaluation Period
研究概览
简要总结
BCD-131 is pegylated darbepoetin beta. BCD-131-2 is International Multicenter Randomized Open-Label Comparative Study (Phase II) of the Efficacy and Safety of BCD-131 and Mircera in Treatment of Anemia in Chronic Kidney Disease Patients on Dialysis.
详细描述
The hypothesis of the study is that the efficacy of BCD-131 is equivalent to that of Mircera® based on the analysis of the primary endpoint (changes in the Hb level over the period of evaluation as compared to the baseline Hb level ) during the 21-week period of treatment.
This study is a study of the maintenance treatment of anemia. The study will include up to 100 dialysis patients with stage 5D chronic kidney disease, established efficacy of dialysis and renal anemia without other causes of anemia, receiving erythropoiesis-stimulating agents (ESA) and reaching target hemoglobin levels.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 75 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Signed written informed consent.
- •Men and women aged from 18 to 75 years (inclusive) on the day of signing informed consent;
- •End-stage kidney disease.
- •Need for dialysis for at least 3 months before signing informed consent.
- •Need for at least 12 hours on standard dialysis procedure weekly.
- •rHuEpo (epoetin alpha, epoetin beta, darbepoetin alpha) administration for at least 3 months before signing informed consent.
- •Regular rHuEpo (epoetin alfa, epoetin beta, darbepoetin alfa) administration 1, 2 or 3 times a week (stable dose, stable frequency) before signing informed consent.
- •Target hemoglobin level (100-120 g/l) for at least 3 months before signing informed consent.
- •Effective dialysis dose index (Kt/v) ≥1.2 for patients receiving hemodialysis and (Kt/v) ≥1.7 for patients receiving peritoneal dialysis.
- •TSAT ≥20%, Serum ferritin >200 ng/ml.
- •Patients and their sexual partners with childbearing potential must implement reliable contraceptive measures during all the study treatment, starting 4 weeks prior to the administration of the first dose of investigational product until 4 weeks after the last dose of investigational product. This requirement does not apply to participants who have undergone surgical sterilization. Reliable contraceptive measures include two methods of contraception, including one barrier method/
- •Patients should be able to follow the Protocol procedures
排除标准
- •Any other causes of anemia except for renal anemia, including folate and B12 deficiency, chronic blood loss, aluminium intoxication, sickle-cell anemia, chronic disease anemia (CRP above 20 mg/l), refractory anemia with blast cells in peripheral blood.
- •Lupus nephritis of kidney disease due to systemic vasculitis.
- •Platelet count below 100х10^9 cells/l.
- •Scheduled kidney transplant during study participation period.
- •Hypersensitivity to darbepoetin alfa or of any components of study drugs, or to Fe (III)-hydroxide-sucrose complex.
- •Vaccination less than 8 weeks before signing informed consent.
- •Liver cirrhosis with portal hypertension and/or splenomegaly and/or ascitis.
- •HIV infection, active HBV, HCV.
- •ALT, AST level above 3x ULN.
- •Congestive heart failure (Grade IV NYHA)
- •Resistant arterial hypertension.
- •Unstable angina.
- •Hemoglobinopathy, MDS, hematologic malignancy, PRCA.
- •Severe secondary hyperparathyroidism.
- •Gastrointestinal bleeding history.
- •Thrombotic events history (myocardial infarction, stroke, TIA, DVT, PATE) less than 6 months before signing informed consent.
- •Seizures, including epilepsy.
- •Major surgery in less than 1 month before signing informed consent
- •Blood transfusions in less than 3 months before signing informed consent.
- •Acute inflammatory diseases or exacerbations of chronic inflammation.
- •Severe psychiatric disorders and suicidal ideation and suicidal behavior.
- •History of malignancy, excluding appropriately treated basal cell carcinoma or cervical carcinoma in situ.
- •Alcohol or drug abuse.
- •Simultaneous participation in other trials or in less than 3 months before signing informed consent
- •Pregnancy of breast-feeding.
结局指标
主要结局
Change in Hemoglobin (Hb) Concentration From Baseline to the Evaluation Period
时间窗: Baseline - measurements on Screening (weeks -4 - 0) and on day 1; Evaluation period - weekly measures on weeks 21 to 23
The baseline hemoglobin will be calculated as the arithmetic mean of hemoglobin values obtained at screening and at Visit 1. The final hemoglobin value during the evaluation period will be calculated as the arithmetic mean of hemoglobin values obtained at Week 21 and Week 23.
次要结局
- AUC(0-∞)(3, 6, 12, 24, 48, 72, 96, 168, 336, 504, 672 h h after injection 1, weeks 5, 9, 13, 17, 21)
- AC-Emax(day 28)
- The Proportion of Patients Who Developed AEs/SAEs That, in the Investigator's Opinion, Are Related to BCD-131(Week 23)
- The Proportion of BAb- and NAb-positive Patients(Week 9, 23)
- AUC(0-672 Hour)(3, 6, 12, 24, 48, 72, 96, 168, 336, 504, 672 h h after injection 1)
- Cmax(3, 6, 12, 24, 48, 72, 96, 168, 336, 504, 672 h h after injection 1, weeks 5, 9, 13, 17, 21)
- AUEC(0-672 Hour)(3, 6, 12, 24, 48, 72, 96, 168, 336, 504, 672 h h after injection 1)
研究者
研究点 (4)
Loading locations...
相似试验
进行中（未招募）
不适用
A Randomized Open-Label Study of Darbepoetin alfa Administered Every Three Weeks with or without Parenteral Iron in Anemic Subjects with Nonmyeloid Malignancies Receiving ChemotherapyEUCTR2004-001417-33-ITAMGE
进行中（未招募）
1 期
A Randomized Open-Label Study of Darbepoetin alfa Administered Every Three Weeks with or without Parenteral Iron in Anemic Subjects with Nonmyeloid Malignancies Receiving Chemotherapy - AIM 3: Anemia and Iron Management with every 3 week dosingChemotherapy induced anemiaMedDRA version: 7.0Level: PTClassification code 10049105EUCTR2004-001417-33-GBAmgen Inc400
进行中（未招募）
不适用
A Randomized Open-Label Study of Darbepoetin alfa Administered Every Three Weeks with or without Parenteral Iron in Anemic Subjects with Nonmyeloid Malignancies Receiving Chemotherapy - AIM 3: Anemia and Iron Management with every 3 week dosingChemotherapy induced anemiaMedDRA version: 7.0Level: PTClassification code 10049105EUCTR2004-001417-33-SEAmgen Inc400
进行中（未招募）
不适用
A Randomized Open-Label Study of Darbepoetin alfa Administered Every Three Weeks with or without Parenteral Iron in Anemic Subjects with Nonmyeloid Malignancies Receiving Chemotherapy - AIM 3: Anemia and Iron Management with every 3 week dosingEUCTR2004-001417-33-HUAmgen Inc400
进行中（未招募）
不适用
A Randomized Open-Label Study of Darbepoetin alfa Administered Every Three Weeks with or without Parenteral Iron in Anemic Subjects with Nonmyeloid Malignancies Receiving Chemotherapy - AIM 3: Anemia and Iron Management with every 3 week dosingChemotherapy induced anemiaMedDRA version: 7.0Level: PTClassification code 10049105EUCTR2004-001417-33-DKAmgen Inc400